A detailed history of Driehaus Capital Management LLC transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Driehaus Capital Management LLC holds 445,352 shares of PTGX stock, worth $20.7 Million. This represents 0.2% of its overall portfolio holdings.

Number of Shares
445,352
Previous 556,835 20.02%
Holding current value
$20.7 Million
Previous $19.3 Million 3.73%
% of portfolio
0.2%
Previous 0.21%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$33.72 - $47.33 $3.76 Million - $5.28 Million
-111,483 Reduced 20.02%
445,352 $20 Million
Q2 2024

Aug 14, 2024

SELL
$24.66 - $34.8 $91,118 - $128,585
-3,695 Reduced 0.66%
556,835 $19.3 Million
Q1 2024

May 15, 2024

BUY
$21.79 - $32.15 $7.88 Million - $11.6 Million
361,841 Added 182.11%
560,530 $16.2 Million
Q4 2023

Feb 14, 2024

BUY
$14.05 - $23.44 $2.79 Million - $4.66 Million
198,689 New
198,689 $4.56 Million

Others Institutions Holding PTGX

About Protagonist Therapeutics, Inc


  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $2.28B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Driehaus Capital Management LLC Portfolio

Follow Driehaus Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Driehaus Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Driehaus Capital Management LLC with notifications on news.